# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Jason Bednar maintains Pulmonx (NASDAQ: LUNG) with a Overweight and lowers the price target from $14 t...
Canaccord Genuity analyst Jon Young maintains Pulmonx (NASDAQ:LUNG) with a Buy and raises the price target from $15 to $16.
Wells Fargo analyst Larry Biegelsen maintains Pulmonx (NASDAQ:LUNG) with a Equal-Weight and lowers the price target from $14...
Pulmonx (NASDAQ:LUNG) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.44) by 11...
Lake Street analyst Frank Takkinen initiates coverage on Pulmonx (NASDAQ:LUNG) with a Buy rating and announces Price Target ...
Canaccord Genuity analyst Jon Young maintains Pulmonx (NASDAQ:LUNG) with a Buy and lowers the price target from $16 to $15.
ALLR: 151% | Allarity Therapeutics shares are trading higher after the company announced that Stenoparib shows a clear clinical...